Humanin vs SS-31 (Elamipretide)
A side-by-side research comparison of Humanin and SS-31 (Elamipretide) across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Humanin | SS-31 (Elamipretide) |
|---|---|---|
| Full name | Humanin (HN) Mitochondrial-Derived Peptide | SS-31 / Elamipretide (Bendavia) |
| Category | Anti-Aging | Anti-Aging |
| Status | Research compound | Investigational |
| Mechanism | Binds IGFBP-3, BAX, and trimeric receptor (CNTFR/WSX-1/gp130) to activate STAT3. Inhibits mitochondrial apoptosis and provides neuroprotection. | Targets cardiolipin in inner mitochondrial membrane, stabilizes cytochrome c binding, optimizes electron transfer efficiency, and reduces mitochondrial ROS by 50%. |
| Molecular weight | 2,687 Da | 640.8 Da |
| Half-life | 4-6 hours | 4-6 hours |
| Bioavailability | Moderate (SubQ) | High (SubQ) |
| Typical dose | 1-5 mg | 5-40 mg |
| Frequency | 3-5x per week | Daily |
| Route | Subcutaneous | Subcutaneous or IV |
Humanin reported benefits
- Neuroprotection against amyloid-beta
- Anti-apoptotic
- Improved insulin sensitivity
- Cardioprotection
- Cellular stress resistance
SS-31 (Elamipretide) reported benefits
- Mitochondrial function optimization
- Reduced oxidative stress
- Cardioprotection
- Improved exercise capacity
- Renal protection
- Cellular energy
Related comparisons
Research and educational reference only. Not medical advice.